异常凝血酶原在肝细胞癌中的价值

Value of serum abnormal prothrombin in hepatocellular carcinoma

肝细胞癌(HCC)起病隐匿,早期诊断困难,死亡率较高。传统的标志物甲胎蛋白(AFP)在HCC的诊断上存在一些局限,因此寻找新型血清学标志物一直是HCC相关研究的焦点。PIVKA-Ⅱ是一种异常凝血酶原,有研究表明其对HCC的诊断价值较高,且与HCC细胞增殖存在密切联系,在日本已被用于HCC高危人群的监测,并能用来评估HCC的治疗效果,预测肝癌患者的预后。

Hepatocellular carcinoma(HCC) is insidious in onset, difficult in early diagnosis and with a considerable mortality. The related researches of HCC have been focused on searching for the new serological markers because of the alpha-fetoprotein(AFP), a tradition marker, existing some limitations in the diagnosis of HCC. Protein induced by vitamin K absence or antagonist-Ⅱ(PIVAKA-Ⅱ), an abnormal prothrombin, has been proved to show its high potential diagnostic value to HCC and a close association with the proliferation of HCC. In Japan, it has been used in monitoring the high-risk groups of HCC, evaluating the therapeutic effect and predicting the prognosis of HCC patients.